Pasithea therapeutics selects pas-003 lead development candidate, a humanized monoclonal antibody that targets Α5Β1 integrin for the treatment of both sporadic and familial als

Pasithea tx (nasdaq: ktta) selects lead development candidate, humanized mab that targets Α5Β1 integrin for treatment of both sporadic and familial als

KTTA Ratings Summary

KTTA Quant Ranking